文献速递心力衰竭与心肌病高血压

恩格列净在难治性高血压合并射血分数保留心衰中的研究:EMPEROR-Preserved 试验

Empagliflozin in resistant hypertension and heart failure with preserved ejection fraction: the EMPEROR-Preserved trial.
PubMed 文献 · Eur Heart J · 2025-01-01

本研究基于 EMPEROR-Preserved 试验的 5533 例患者,将高血压分为难治性、未控制和控制三类,探索恩格列净对收缩压、目标范围内时间、高血压急症及心血管肾脏结局的影响。结果显示恩格列净在早期对难治性高血压的收缩压降幅略大,但整体治疗效应在各高血压类别间无差异,提示适度血压调节不影响恩格列净的总体获益。

要点

  • HFpEF 中难治性高血压患病率高,且结局事件率高于控制或未控制高血压。
  • 恩格列净对主要终点、eGFR 斜率及生活质量改善的效应不受高血压类别影响。
  • 恩格列净适度降低收缩压并增加目标范围内时间,减少高血压急症。

核心结论

  • 在 HFpEF 中难治性高血压患病率高且结局事件率更高,但恩格列净的治疗效应不受高血压类别修饰。

研究设计与样本

  • 基于 EMPEROR-Preserved 试验的 5533 例患者,按难治性、未控制和控制高血压分组,采用校正混杂因素的 Cox 回归和混合效应模型分析。

主要发现

  • 恩格列净在最初几周对难治性高血压的收缩压降幅略大于其他类别,之后无显著差异。
  • 收缩压适度降低使目标范围内时间中度增加并减少高血压急症。
  • 主要终点在难治性高血压中更常见(P = .0358)。
  • 恩格列净对主要终点的治疗效应在难治性、未控制和控制高血压间相似(交互 P = .92)。
  • 恩格列净对 eGFR 斜率改善(交互 P = .95)和生活质量变化的影响在各高血压类别间无差异。

临床怎么用

  • HFpEF 合并难治性高血压患者仍可从恩格列净治疗中获益,无需因血压控制状态调整用药预期。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Hypertension has a high prevalence in heart failure with preserved ejection fraction (HFpEF), which can be controlled, uncontrolled, or even resistant. The effects of empagliflozin on systolic blood pressure (SBP), time in target range, incidence of hypertensive urgencies, and studied cardiovascular and renal outcomes in different hypertension categories and after treatment with empagliflozin in the EMPEROR-Preserved trial were explored. METHODS: A total of 5533 patients were studied and the population was separated into resistant (resHTN), uncontrolled (uctrHTN), and controlled (ctrHTN) hypertension. The effect of SBP on outcomes and treatment effects of empagliflozin were explored. Analyses were done with Cox regression analyses adjusted for demographic and clinical confounders and with a mixed model for repeated measures. RESULTS: Empagliflozin reduced SBP in resHTN slightly more than in the other categories in the first weeks, while thereafter there were no significant differences. The modest reduction in SBP resulted in a moderate increase in time at target and reduced hypertensive urgencies. The primary endpoint was more prevalent in resHTN (P = .0358), but the treatment effect of empagliflozin on the primary endpoint was similar in resHTN, uctrHTN, and ctrHTN (P for interaction = .92) as was the improvement of the estimated glomerular filtration rate slope (P for interaction = .95) and change in quality of life by empagliflozin. CONCLUSIONS: In HFpEF, the prevalence of resHTN is high and is associated with frequently higher outcome rates compared with ctrHTN and uctrHTN. The treatment effect was not modified by hypertension categories. This indicates that in HFpEF, moderate modifications of blood pressure do not affect overall outcomes and treatment effects of empagliflozin.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Böhm, Butler, Coats, et al. Empagliflozin in resistant hypertension and heart failure with preserved ejection fraction: the EMPEROR-Preserved trial. Eur Heart J. 2025. PMID: 40037646. doi:10.1093/eurheartj/ehae938

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。